Clinical Trial Update: Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating immunomodulation with naltrexone and ketamine for COVID-19 was terminated; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Ketamine (ketamine)
• Naltrexone (Naltrexone)

Snippet

Sponsor: Corewell Health East | Conditions: COVID-19, Acute Respiratory Distress Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2022-01-26